These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 14677005)

  • 1. Treatment of overactive bladder with botulinum toxin type B: a pilot study.
    Dykstra D; Enriquez A; Valley M
    Int Urogynecol J Pelvic Floor Dysfunct; 2003 Dec; 14(6):424-6. PubMed ID: 14677005
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Botulinum toxins types A and B for brow furrows: preliminary experiences with type B toxin dosing.
    Lowe NJ; Yamauchi PS; Lask GP; Patnaik R; Moore D
    J Cosmet Laser Ther; 2002 Mar; 4(1):15-8. PubMed ID: 12079632
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Botulinum toxin A and B: a comparative dosing study for spasmodic dysphonia.
    Blitzer A
    Otolaryngol Head Neck Surg; 2005 Dec; 133(6):836-8. PubMed ID: 16360499
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pilot study of the safety and efficacy of Myobloc (botulinum toxin type B) for treatment of axillary hyperhidrosis.
    Baumann L; Slezinger A; Halem M; Vujevich J; Martin LK; Black L; Bryde J
    Int J Dermatol; 2005 May; 44(5):418-24. PubMed ID: 15869543
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Double-blind, randomized, placebo-controlled pilot study of the safety and efficacy of Myobloc (botulinum toxin type B) for the treatment of palmar hyperhidrosis.
    Baumann L; Slezinger A; Halem M; Vujevich J; Mallin K; Charles C; Martin LK; Black L; Bryde J
    Dermatol Surg; 2005 Mar; 31(3):263-70. PubMed ID: 15841624
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of botulinum toxin B on refractory detrusor overactivity: a randomized, double-blind, placebo controlled, crossover trial.
    Ghei M; Maraj BH; Miller R; Nathan S; O'Sullivan C; Fowler CJ; Shah PJ; Malone-Lee J
    J Urol; 2005 Nov; 174(5):1873-7; discussion 1877. PubMed ID: 16217327
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Botulinum toxin type B in piriformis syndrome.
    Lang AM
    Am J Phys Med Rehabil; 2004 Mar; 83(3):198-202. PubMed ID: 15043354
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Botulinum B treatment of the glabellar and frontalis regions: a dose response analysis.
    Spencer JM; Gordon M; Goldberg DJ
    J Cosmet Laser Ther; 2002 Mar; 4(1):19-23. PubMed ID: 12079633
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Botulinum toxin type B (MyoBloc) in the management of hyperkinetic facial lines.
    Ramirez AL; Reeck J; Maas CS
    Otolaryngol Head Neck Surg; 2002 May; 126(5):459-67. PubMed ID: 12075218
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BotB (botulinum toxin type B): evaluation of safety and tolerability in botulinum toxin type A-resistant cervical dystonia patients (preliminary study).
    Truong DD; Cullis PA; O'Brien CF; Koller M; Villegas TP; Wallace JD
    Mov Disord; 1997 Sep; 12(5):772-5. PubMed ID: 9380065
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Botulinum toxin type B for glabellar wrinkles: a prospective open-label response study.
    Sadick NS; Faacs
    Dermatol Surg; 2002 Sep; 28(9):817-21. PubMed ID: 12269875
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bladder instillation of liposome encapsulated onabotulinumtoxina improves overactive bladder symptoms: a prospective, multicenter, double-blind, randomized trial.
    Chuang YC; Kaufmann JH; Chancellor DD; Chancellor MB; Kuo HC
    J Urol; 2014 Dec; 192(6):1743-9. PubMed ID: 25046622
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Botulinum neurotoxin serotypes A and B preparations have different safety margins in preclinical models of muscle weakening efficacy and systemic safety.
    Roger Aoki K
    Toxicon; 2002 Jul; 40(7):923-8. PubMed ID: 12076646
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Botulinum toxin urethral sphincter injection to restore bladder emptying in men and women with voiding dysfunction.
    Phelan MW; Franks M; Somogyi GT; Yokoyama T; Fraser MO; Lavelle JP; Yoshimura N; Chancellor MB
    J Urol; 2001 Apr; 165(4):1107-10. PubMed ID: 11257648
    [TBL] [Abstract][Full Text] [Related]  

  • 15. OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo-controlled trial.
    Chapple C; Sievert KD; MacDiarmid S; Khullar V; Radziszewski P; Nardo C; Thompson C; Zhou J; Haag-Molkenteller C
    Eur Urol; 2013 Aug; 64(2):249-56. PubMed ID: 23608668
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Emerging role of botulinum toxin in the management of voiding dysfunction.
    Smith CP; Chancellor MB
    J Urol; 2004 Jun; 171(6 Pt 1):2128-37. PubMed ID: 15126771
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Botulinum toxin type B in the treatment of residual limb hyperhidrosis for lower limb amputees: a pilot study.
    Kern U; Kohl M; Seifert U; Schlereth T
    Am J Phys Med Rehabil; 2011 Apr; 90(4):321-9. PubMed ID: 21765248
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Botulinum toxin type B for type A resistant bladder spasticity.
    Pistolesi D; Selli C; Rossi B; Stampacchia G
    J Urol; 2004 Feb; 171(2 Pt 1):802-3. PubMed ID: 14713821
    [No Abstract]   [Full Text] [Related]  

  • 19. Botulinum toxin B is not an effective treatment of refractory overactive bladder.
    Hirst GR; Watkins AJ; Guerrero K; Wareham K; Emery SJ; Jones DR; Lucas MG
    Urology; 2007 Jan; 69(1):69-73. PubMed ID: 17270619
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dose-finding, safety, and tolerability study of botulinum toxin type B for the treatment of hyperfunctional glabellar lines.
    Carruthers A; Carruthers J; Flynn TC; Leong MS
    Dermatol Surg; 2007 Jan; 33(1 Spec No.):S60-8. PubMed ID: 17241416
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.